$-0.31 EPS Expected for Celsion Corporation (CLSN)

February 24, 2018 - By Adrian Mccoy

 $ 0.31 EPS Expected for Celsion Corporation (CLSN)

Analysts expect Celsion Corporation (NASDAQ:CLSN) to report $-0.31 EPS on March, 15.They anticipate $1.65 EPS change or 84.18 % from last quarter’s $-1.96 EPS. After having $-0.39 EPS previously, Celsion Corporation’s analysts see -20.51 % EPS growth. The stock decreased 3.11% or $0.07 during the last trading session, reaching $2.18. About 201,154 shares traded. Celsion Corporation (NASDAQ:CLSN) has declined 82.71% since February 24, 2017 and is downtrending. It has underperformed by 99.41% the S&P500.

Celsion Corporation (NASDAQ:CLSN) Ratings Coverage

Among 2 analysts covering Celsion (NASDAQ:CLSN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Celsion had 9 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Hold” rating by Maxim Group given on Tuesday, August 15. Maxim Group maintained Celsion Corporation (NASDAQ:CLSN) rating on Tuesday, January 19. Maxim Group has “Buy” rating and $9.0 target. The rating was maintained by Cantor Fitzgerald with “Buy” on Friday, August 7. On Monday, August 7 the stock rating was maintained by Maxim Group with “Hold”. The stock of Celsion Corporation (NASDAQ:CLSN) earned “Hold” rating by Maxim Group on Thursday, November 10. The rating was upgraded by Maxim Group on Thursday, October 5 to “Buy”. On Thursday, June 1 the stock rating was maintained by Maxim Group with “Hold”. Zacks upgraded the shares of CLSN in report on Wednesday, August 12 to “Hold” rating. The rating was initiated by Oppenheimer on Monday, November 20 with “Buy”.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company has market cap of $38.66 million. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It currently has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

More recent Celsion Corporation (NASDAQ:CLSN) news were published by: Globenewswire.com which released: “Celsion Corporation Provides Corporate Update and 2018 Outlook” on January 18, 2018. Also Globenewswire.com published the news titled: “Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides …” on November 14, 2017. Globenewswire.com‘s news article titled: “Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer …” with publication date: February 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: